Bristol Myers axes Immatics` bispecific after $150M bet
16 Sep 2024 //
FIERCE BIOTECH
BMS Shows 10-Year Survival Data For Opdivo-Yervoy In Advanced Melanoma
15 Sep 2024 //
BUSINESSWIRE
GSK`s Zejula Misses Survival Goal In First-Line Ovarian Cancer
14 Sep 2024 //
FIERCE PHARMA
Bristol Myers Squibb To Report Q3 2024 Results On October 31
12 Sep 2024 //
BUSINESSWIRE
PanTera Attracts $102.5M In Series A For Radiopharmaceutical Manufacturing
12 Sep 2024 //
ENDPTS
Bristol Myers Squibb Starts 3,000-Mile Cancer Fundraising Bike Ride
09 Sep 2024 //
FIERCE PHARMA
Zenas BioPharma Seeks $689.7M Valuation In US IPO
06 Sep 2024 //
REUTERS
Bristol Myers Squibb Employees Relay For V Foundation Cancer Research
06 Sep 2024 //
BUSINESSWIRE
Bayer`s asundexian failed to prevent strokes, imperiling $5.5B blockbuster hopes
03 Sep 2024 //
FIERCE BIOTECH
Long-Term Data Confirms CAMZYOS® Efficacy In Symptomatic oHCM Patients
01 Sep 2024 //
BUSINESSWIRE
Neurocrine`s drug cuts schizophrenia symptoms in mid-stage study
29 Aug 2024 //
REUTERS
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
27 Aug 2024 //
BUSINESSWIRE
Bristol Myers Squibb To Present Cardiovascular Data At ECS 2024
27 Aug 2024 //
INDIANPHARMAPOST
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
22 Aug 2024 //
REUTERS
BMS Receives FDA sBLA Acceptance For Hepatocellular Carcinoma Drug
22 Aug 2024 //
BUSINESSWIRE
EMA Validates BMS`s CAR T Therapy Breyanzi For Follicular Lymphoma
19 Aug 2024 //
BUSINESSWIRE
Bristol’ schizophrenia drug nears approval, AbbVie hope to provide competition
19 Aug 2024 //
BIOPHARMADIVE
EMA Validates BMS` Application For Breyanzi CAR T In Follicular Lymphoma
19 Aug 2024 //
INDIANPHARMAPOST
Incyte`s blood cancer drug succeeds late-stage trial
16 Aug 2024 //
REUTERS
Abata Therapeutics Gets Bristol Myers Investment For Treg Cell Therapy
15 Aug 2024 //
GLOBENEWSWIRE
US FDA approves Citius` therapy for rare blood cancer
09 Aug 2024 //
REUTERS
FDA blasts Bristol Myers over misleading Krazati efficacy claims
08 Aug 2024 //
FIERCE PHARMA
Evotec Progresses In Neuroscience Partnership With Bristol Myers Squibb
08 Aug 2024 //
ACCESSWIRE
BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific
05 Aug 2024 //
FIERCE BIOTECH
Bristol Myers Announces 117 Layoffs In New Jersey
05 Aug 2024 //
FIERCE PHARMA
Galapagos pauses CAR-T cell therapy trial over Parkinsonism case
03 Aug 2024 //
FIERCE BIOTECH
Kexing Biopharm`s Albumin-bound Paclitaxel Granted EU Market Approval
31 Jul 2024 //
PR NEWSWIRE
BMS axes bispecific months after filing to run phase 3 trial
27 Jul 2024 //
FIERCE BIOTECH
Bristol Myers CEO Confident In Handling IRA Pricing On Eliquis
26 Jul 2024 //
FIERCE PHARMA
Bristol Myers Squibb Supports All Marketed Products With Access Plans
26 Jul 2024 //
ACCESSWIRE
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
26 Jul 2024 //
BUSINESSWIRE
Argenx`s Vyvgart Competes Well With AstraZeneca In Myasthenia Gravis
25 Jul 2024 //
FIERCE PHARMA
Drug giants eye China for deals despite growing Sino-US tensions
23 Jul 2024 //
REUTERS
BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer
20 Jul 2024 //
PRESS RELEASE
Bristol Myers Squibb Receives EMA Validation For Opdivo Plus Yervoy
19 Jul 2024 //
BUSINESSWIRE
Aveo`s Fotivda fail as combo in kidney cancer
19 Jul 2024 //
FIERCE PHARMA
Bristol Myers Squibb Reaches Major Milestone in Environmental Sustainability
18 Jul 2024 //
ACCESSWIRE
J&J, BMS and AZ appeal IRA litigation losses
16 Jul 2024 //
FIERCE PHARMA
Bristol Myers’ leukemia blockbuster set to face generic rivals
13 Jul 2024 //
BIOPHARMADIVE
Abecma competition, Sotyktu pricing pressure and IRA: Analysts outline BMS
12 Jul 2024 //
FIERCE PHARMA
Bristol Myers Squibb To Join UBS Virtual Protein Degradation Day
08 Jul 2024 //
BUSINESSWIRE
LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus
03 Jul 2024 //
PR NEWSWIRE
Japan`s Eisai terminates ADC manufacturing pact with BMS
03 Jul 2024 //
BIOSPECTRUM ASIA
BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival
02 Jul 2024 //
FIERCE BIOTECH
As former BMS CEO Giovanni Caforio plots move to Novartis
01 Jul 2024 //
FIERCE PHARMA
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America
28 Jun 2024 //
ACCESSWIRE
US FDA approves Bristol Myers` colorectal cancer therapy
22 Jun 2024 //
REUTERS
EMA Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
21 Jun 2024 //
BUSINESSWIRE
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
20 Jun 2024 //
BUSINESSWIRE
US study suggests BMS’ cancer drug could target Parkinson’s-causing protein
20 Jun 2024 //
PHARMATIMES
Bristol Myers Squibb Announces Dividend
18 Jun 2024 //
BUSINESSWIRE
Bristol Myers Squibb Elects Michael R. McMullen To Board Of Directors
18 Jun 2024 //
BUSINESSWIRE
Innovent links IL-2 fusion protein to responses in small study
15 Jun 2024 //
FIERCE PHARMA
EU regulator requires secondary cancer risk warning for CAR-T therapies
15 Jun 2024 //
REUTERS
BMS bags FDA tumor-agnostic nod to challenge Bayer, Roche
14 Jun 2024 //
FIERCE PHARMA
BMS scores tumour-agnostic nod for Augtyro across NTRK fusion cancers
14 Jun 2024 //
PRESS RELEASE
Evotec Reaches Milestone in Neuroscience Collaboration with Bristol Myers Squibb
13 Jun 2024 //
PHARMABIZ
Novo, Novartis, BMS among pharmas celebrating LGBTQ+ Pride month
12 Jun 2024 //
FIERCE PHARMA
BMS` dealmaking appetite remains intact, CEO says
12 Jun 2024 //
FIERCE PHARMA
Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu
10 Jun 2024 //
BIOPHARMADIVE